Market
Will 5 African countries adopt Lenacapavir for HIV prevention by 2026?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from African health ministries or Gilead press releases
Story
Global Leaders Back Lenacapavir, Gilead's HIV Drug with 100% Efficacy in Phase 3 Testing, Single Shot Every Year
Dec 15, 2024, 03:44 PM
Global leaders are uniting to support the development of an injectable medication aimed at eradicating HIV. Gilead Sciences announced plans to initiate Phase 3 testing for Lenacapavir, a drug that could potentially prevent HIV infection with just a single annual injection. This medication has been recognized as a significant scientific advancement, with reports highlighting its remarkable efficacy. A large trial conducted in June involving African adolescent girls and young women demonstrated that the treatment reduced HIV infections to zero, achieving an efficacy rate of 100%. This finding was corroborated by a subsequent trial conducted across multiple regions three months later, reinforcing the drug's potential impact in the fight against HIV/AIDS.
View original story
Similar markets
Uganda • 25%
South Africa • 25%
Both countries • 25%
Neither country • 25%
United States • 25%
Other • 25%
India • 25%
South Africa • 25%
USA • 25%
Other • 25%
South Africa • 25%
UK • 25%
No • 50%
Yes • 50%
Africa • 25%
Other • 25%
European Union • 25%
United States • 25%
Reduction by less than 5% • 25%
Reduction by 5% to 10% • 25%
Reduction by 10% to 15% • 25%
Reduction by more than 15% • 25%
20% to 40% • 25%
More than 60% • 25%
Less than 20% • 25%
40% to 60% • 25%